Business Standard

Jubilant Life Sciences receives ANDA approvals for Valsartan Tablets

Image

Capital Market

From USFDA

Jubilant Life Sciences announced that it has received Abbreviated New Drug Application (ANDA) final approval from the US Food and Drug Administration (US FDA) for Valsartan Tablets USP, 40 mg, 80 mg, 160 mg and 320 mg, the generic version of Diovan (of Novartis), used as an anti-hypertensive.

Powered by Capital Market - Live News

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jan 06 2015 | 3:53 PM IST

Explore News